Arrowhead hits the mark with interim phase II data in rare liver disease Sep. 16, 2020 By Lee Landenberger The positive interim 24-week liver biopsy results from Arrowhead Pharmaceuticals Inc.’s open-label phase II of its RNAi-based liver-targeted therapeutic, ARO-AAT, came as a surprise to the developers.Read More